Exhibit 99.1 CLEARMIND MEDICINE INC. Condensed Interim Consolidated Financial Statements For The Three Months Ended January 31, 2024 (Expressed in United States Dollars) (Unaudited) CLEARMIND MEDICINE INC. Condensed Interim Consolidated Statements of Financial Position (Expressed in United States Dollars) (Unaudited) January 31, October 31, 2024 2023 Assets Current assets Cash and cash equivalents $ 9,285,973 $ 5,427,739 Other receivables 68,491 104,320 Short-term investment (Note 3) 86,668 86,112 Prepaid e ...

Vancouver, Canada, March 13, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. ((Nasdaq, CSE:CMND), (FSE: CWY) ("Clearmind" or the "company"), a clinical- stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, announced that it has received approval from the Israeli Ministry of Health to commence its phase I/IIa clinical trial for alcohol use disorder (AUD) patients using the company's proprietary MEAI-based (5- metho ...

公司退市 - Clearmind Medicine Inc.宣布已申请并获得了从加拿大证券交易所(CSE)自愿退市的批准[1] - 公司认为其股票在CSE上的交易量不再能够证明维持双重上市所需的费用和行政工作[2] - 退市后，Clearmind的股东可以通过他们的经纪人在纳斯达克交易他们的普通股[4] 公司业务 - Clearmind是一家致力于发现和开发新型基于致幻物质的治疗药物的致幻药物生物技术公司[5]

公司概况 - Clearmind Medicine Inc.是一家专注于发现和开发新型基于致幻物质的治疗药物的生物技术公司[1] - 公司在中国国家知识产权局获得了分部专利批准，进一步巩固了其在致幻物质领域的知识产权保护[1] - Clearmind拥有包括24项待批专利申请和27项已批专利在内的15个实用专利家族，覆盖美国、欧洲、中国和印度等主要司法管辖区[2] 新型心理活性分子MEAI - MEAI是一种新型的心理活性分子，可以减少对酒精饮料的渴望，同时产生类似于酒精的轻微愉悦体验，有潜力改变那些无法适度饮酒的人的生活[3]

The licensing agreement refers to the company's dedicated treatment for cocaine addiction which previously indicated a significant decrease in cocaine craving Tel Aviv, Israel / Vancouver, Canada, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. ((Nasdaq, CSE:CMND), (FSE: CWY) ("Clearmind" or the "company"), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced the signing of an exclusive long-t ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended October 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of eve ...

Exhibit 99.1 CLEARMIND MEDICINE INC. Condensed Interim Consolidated Financial Statements For The Three and Nine Months Ended July 31, 2023 (Expressed in United States Dollars) (Unaudited) CLEARMIND MEDICINE INC. Condensed Interim Consolidated Statements of Financial Position (Expressed in United States Dollars) (Unaudited) July 31, October 31, 2023 2022 Assets Current assets Cash and cash equivalents $ 3,847,259 $ 128,777 Other receivables 108,255 50,933 Short-term investment (Note 3) 122,779 193,750 Prepai ...

Exhibit 99.1 CLEARMIND MEDICINE INC. Condensed Interim Consolidated Financial Statements For The Three and Six Months Ended April 30, 2023 (Expressed in United States Dollars) (Unaudited) CLEARMIND MEDICINE INC. Condensed Interim Consolidated Statements of Financial Position (Expressed in United States Dollars) (Unaudited) April 30, October 31, 2023 2022 Assets Current assets Cash and cash equivalents $ 5,245,707 $ 128,777 Other receivables 109,625 50,933 Short-term investment (Note 3) 135,001 193,750 Prepa ...

Exhibit 99.1 CLEARMIND MEDICINE INC. Condensed Interim Consolidated Financial Statements For The Three Months Ended January 31, 2023 (Expressed in Canadian Dollars) (Unaudited) CLEARMIND MEDICINE INC. Condensed Interim Consolidated Statements of Financial Position (Expressed in Canadian Dollars) (Unaudited) January 31, October 31, 2023 2022 Assets Current assets Cash and cash equivalents $ 4,498,048 $ 175,768 Other receivables 291,829 69,518 Short-term investment (Note 3) 180,225 264,449 Prepaid expenses 93 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 20-F Commission File No.: 001-41557 Clearmind Medicine Inc. (Exact name of registrant as specified in its charter) Translation of registrant’s name into English: Not applicable 101 – 1220 West 6Avenue British Columbia Vancouver, British Columb ia (Jurisdiction of incorporation or organization) (Address of principal executive offices) Dr. Adi Zuloff-Shani Chief Executive Officer 101 – 1220 West 6 Avenue Vancouver, British Columbia V6 ...